 | | Vol. 22.08 – 8 March, 2021 |
| |
|
|
| Scientists showed that over a two-year period without immunosuppression, Parkinson’s disease monkeys receiving autologous, but not allogenic, transplantation exhibited recovery from motor and depressive signs.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In rodent models of myocardial infarction, investigators demonstrated that intrapericardial injection was an effective and safe method to deliver hydrogels containing induced pluripotent stem cells-derived cardiac progenitor cells or mesenchymal stem cells-derived exosomes.
[Nature Communications] |
|
|
|
| Researchers combined an empiric antibody-based flow cytometry screen with a cyclic immunofluorescence imaging platform and a comprehensive bioinformatical and experimental evaluation for off-tumor expression to identify pancreatic ductal adenocarcinoma-specific cell surface markers.
[Nature Communications] |
|
|
|
| Using bone marrow transplantation and cell type-specific Casp3 knockout mice, scientists demonstrated that Casp3/GSDME-mediated pyroptosis in renal parenchymal cells, but not in hematopoietic cells, played predominant roles in this process.
[Cell Death & Differentiation] |
|
|
|
| Using a novel human prostate stem cell antigen (PSCA) knock-in immunocompetent mouse model, researchers evaluated safety and therapeutic efficacy of PSCA-CAR T cells.
[Molecular Therapy] |
|
|
|
| Co-treatment with BET inhibitor or BET-PROTAC and ibrutinib or venetoclax exerted synergistic in vitro lethality in the diffuse large B cell lymphoma cells.
[Leukemia] |
|
|
|
| Using genome editing with Cas9 ribonucleoprotein and adeno-associated virus serotype 6, the authors integrated a CD19-specific chimeric antigen receptor in-frame into the TRAC locus.
[Haematologica] |
|
|
|
| Researchers showed that hydrodynamic delivery of ribonucleoprotein with SpCas9 protein mixed with synthetic gRNA elicits better genome editing efficiencies than the plasmid vector-based system in mouse liver.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Investigators designed a novel humanized anti-CD19 CAR-T cells by humanizing the framework region of scFv derived from a murine FMC63 mAb and combining it with CD8a transmembrane domain, 4-1BB costimulatory domain and CD3ζ signaling domain.
[Molecular Cancer Therapeutics] |
|
|
|
| Scientists compared the frequencies of different regulatory T cell subtypes in healthy controls as well as in allogeneic hematopoietic cell transplantation patients with or without chronic graft-versus-host disease.
[Bone Marrow Transplantation] |
|
|
|
| Researchers established a single-chain antibody (scFv) generation system in which scFv library-expressing CAR-T cells can be screened appropriately based on their antitumor functions.
[Communications Biology] |
|
|
|
|
| Scientists surveyed the literature to explore the intimate relationship between the inflammatory status of human mesenchymal stem/stromal cell (hMSCs) and their in vitro aging process. They posit that a shift from an anti-inflammatory to a pro-inflammatory phenotype of culture-expanded hMSCs contributes to a deterioration in their therapeutic efficacy.
[Stem Cell Reports] |
|
|
|
| While comparing the outcomes of different haploidentical hematopoietic stem cell transplantation approaches, one must understand the transplant immunobiology and factors affecting the transplant outcomes.
[Bone Marrow Transplantation] |
|
|
|
| The authors focus on the T cell receptor (TCR)-like CARs and TCR-CARs directed against tumor-derived epitopes, with a concerted view on neoepitopes.
[Cancer Gene Therapy] |
|
|
|
|
| AgeX Therapeutics, Inc. and LyGenesis, Inc. announced that they will proceed to negotiate an agreement for a merger of the two companies.
[AgeX Therapeutics, Inc.] |
|
|
|
| Novadip Biosciences announced that the FDA has approved the Company’s Investigational New Drug (IND) application for its autologous cell therapy product NVD‑003 for the treatment of Congenital Pseudarthrosis of the Tibia.
[Novadip Biosciences] |
|
|
|
|
| March 14 – 17, 2021
Virtual |
|
|
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States |
|
|
|
| | Swammerdam Institute for Life Sciences – Amsterdam, The Netherlands |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
